MRUS vs LLY

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -12. 4% for Merus N. V. (MRUS). Eli Lilly and Company (LLY) offers the better valuation at 43. 0x trailing P/E (28. 6x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +421.

4%, compared to +343. 6% for Merus N. V. (MRUS). Over 10 years, the gap is even starker: LLY returned +1272% versus MRUS's +796. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merus N.

V. (MRUS) is the lower-risk stock at 0. 32β versus Eli Lilly and Company's 0. 71β — meaning LLY is approximately 120% more volatile than MRUS relative to the S&P 500. On balance sheet safety, Merus N. V. (MRUS) carries a lower debt/equity ratio of 2% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -12. 4% for Merus N. V. (MRUS). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -11. 7% for Merus N. V.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -595. 9% for Merus N. V. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -753. 0% for MRUS. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LLY: 27.

5% to $1258. 47.

In this comparison, LLY (0.

6% yield) pays a dividend. MRUS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1272% 10Y return). Both have compounded well over 10 years (LLY: +1272%, MRUS: +796. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MRUS is a small-cap quality compounder stock; LLY is a large-cap high-growth stock. LLY pays a dividend while MRUS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.